Akcea Therapeutics, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2020. For the quarter, the company announced total revenue of USD 16.074 million compared to USD 163.816 million a year ago. Loss from operations was USD 45.259 million compared to income from operations of USD 26.207 million a year ago. Net loss was USD 42.850 million compared to net income of USD 27.187 million a year ago. Net loss per basic share of common stock owned by Ionis was $0.42 against earnings per share of $0.35 a year ago.